Arecor Therapeutics plc (AIM:AREC) CEO Sarah Howell presented an overview of the company at the Proactive One2One Investor Forum. Arecor, listed on AIM since 2021, focuses on enhancing existing therapeutic medicines to improve patient care. Howell's background includes product development at GSK and UCB, and she previously led M&A at BTG (LSE:BTG) before its acquisition by Boston Scientific. Arecor leverages a proprietary technology platform to improve the safety, efficacy, and usability of existing medicines. The company partners with major pharma and biotech firms under a milestone and royalty-bearing licensing model. One of their partner products has already been launched, generating recurring royalties. They also have products licensed with companies like Sanofi and Hikma. Arecor's in-house proprietary products target high unmet needs in large markets, focusing on diabetes and obesity. They aim to use their... Watch at #Proactive #ProactiveInvestors http://ow.ly/Iu74105vur3
Proactive’s Post
More Relevant Posts
-
📢 Unlocking Insights into the #DiabetesMarket Explore DelveInsight Business Research LLP's comprehensive Diabetes Market Report for a deep dive into the latest advancements, treatment dynamics, emerging therapies, and market trends transforming diabetes care. The leading #DiabetesCompanies such as Enthera Pharmaceuticals, Nano Precision Medical, Oramed Pharmaceuticals Inc., DOMPE FARMACEUTICI ESPAÑA SL, Carmot Therapeutics, Inc., SCOHIA PHARMA, Inc., Genexine, Inc., REMD BIOTHERAPEUTICS INC. and others. Stay informed and ahead of the curve in understanding the evolving diabetes therapeutics landscape! 📖 Read more @ https://lnkd.in/d7zGT5N4 #DiabetesMarket #DiabetesCare #HealthcareTrends #PharmaInsights #DelveInsight #MarketAnalysis
-
-
Irritable Bowel Syndrome Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Biopharma: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Irritable Bowel Syndrome pipeline constitutes 24+ key companies continuously working towards developing 24+ Irritable Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
-
Ankylosing Spondylitis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ankylosing Spondylitis pipeline constitutes 20+ key companies continuously working towards developing 20+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
Ankylosing Spondylitis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin | ABNewswire
https://www.abnewswire.com/pressreleases
-
Thoughts on this? >> BMS inks deal with AI Proteins; Terns’ early-stage leukemia data >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #biotech #pharma #pharmaceutical
BMS inks deal with AI Proteins; Terns’ early-stage leukemia data
endpts.com
-
Tryptamine Therapeutics Inc. CEO Jason Carroll sits down with Jonathan Jackson in the Proactive studio to talk about the start of trading on the Australian Securities Exchange (ASX). Tryptamine, a clinical-stage biotechnology company, is focused on developing an intravenous-infused psilocin formulation for psychedelic-assisted therapy. The company’s core programs include TRP-8803 (IV-infused psilocin formulation) and TRP-8802 (oral psilocybin). TRP-8803 aims to address the limitations of oral psilocybin, offering a faster onset of the psychedelic state, precise control of the experience, and a shorter duration, making it commercially viable. Three open-label trials in the United States using TRP-8802 for fibromyalgia, irritable bowel syndrome (IBS), and binge eating disorder (BED) are underway or recently completed. Watch at #Proactive #ProactiveInvestors #MentalHealth #PsychedelicAssistedTherapy #Psilocybin #Psilocin https://lnkd.in/eTYscpzf
Tryptamine Therapeutics launches on ASX with innovative psilocin formulation
https://www.youtube.com/
-
According to DelveInsight’s analysis, the global next-generation complement therapeutics market is expected to experience significant growth, with a projected CAGR of ~15% by 2030. In 2023, the biologics segment held a substantial revenue share within the next-generation complement therapeutics market. Prominent companies in this field, including Roche, Amgen, CSL, Innovent Biologics, Novartis, Regeneron, Sanofi, Takeda, and UCB, among others, are actively contributing to the market’s expansion. Get detailed insights here: https://lnkd.in/gKDnf-qe #ComplementTherapeutics #Biologics #HealthcareMarket #Pharmaceuticals #MedicalInnovation #MarketAnalysis #PharmaNews #Biotech #ClinicalTrials #DelveInsight #MedicalResearch #HealthcareInnovation #PharmaDevelopment #PharmaNews #marketgrowth #marketforecast #healthcare #healthcareconsulting #marketresearch #healthcare #pharmaceutical #business #blood #blooddisorder #hematology #chemo #cancerresearch #cancer DelveInsight Business Research LLP
Next Generation Complement Therapeutics Market Size and Share Analysis
delveinsight.com
-
COPD Market Growth Forecast The COPD market in the 7 major markets (7MM) is expected to surge from $11.5B in 2023 to $30.8B by 2033! This growth is driven by major advancements, including the launch of the first biologic for COPD, Dupixent (dupilumab) by Sanofi & Regeneron, and Verona Pharma’s first-in-class treatment Ohtuvayre (ensifentrine). The approval of these pioneering treatments, along with new biologics in the pipeline, will reshape the future of COPD management. The dominance of inhaled corticosteroids (ICS), LABAs, and LAMAs will continue, with biologics & PDE inhibitors enhancing treatment for patients. A big win for patients & the healthcare industry! Want to explore more about this growing market and its impact? Check out GlobalData’s latest report! https://lnkd.in/gz9Kkxet Know more insights here: https://lnkd.in/gv9xG3ra #COPD #Biologics #HealthcareInnovation #Pharma #MarketGrowth #MedicalResearch
-
-
According to DelveInsight’s analysis, the global next-generation complement therapeutics market is expected to experience significant growth, with a projected CAGR of ~15% by 2030. In 2023, the biologics segment held a substantial revenue share within the next-generation complement therapeutics market. Prominent companies in this field, including Roche, Amgen, CSL, Innovent Biologics, Novartis, Regeneron, Sanofi, Takeda, and UCB, among others, are actively contributing to the market’s expansion. Get detailed insights here: https://lnkd.in/gKDnf-qe #ComplementTherapeutics #Biologics #HealthcareMarket #Pharmaceuticals #MedicalInnovation #MarketAnalysis #PharmaNews #Biotech #ClinicalTrials #DelveInsight #MedicalResearch #HealthcareInnovation #PharmaDevelopment #PharmaNews #marketgrowth #marketforecast #healthcare #healthcareconsulting #marketresearch #healthcare #pharmaceutical #business #blood #blooddisorder #hematology #chemo #cancerresearch #cancer DelveInsight Business Research LLP
Next Generation Complement Therapeutics Market Size and Share Analysis
delveinsight.com
-
Dive deep into the world of Phosphodiesterase (PDE) Inhibitors! 🧬 DelveInsight's latest report unveils the cutting-edge developments in PDE inhibitor drugs. With over 40 key companies driving innovation, the global pipeline boasts 40+ promising therapies. 🌐 From clinical trials to FDA approvals, this comprehensive analysis sheds light on the mechanisms, routes of administration, and emerging trends shaping the market. Discover the powerhouses behind PDE inhibitor therapies like Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), Chiesi Group, Imara Inc, Verona Pharma, Eisai Co., Ltd., vTv Therapeutics LLC, Tetra Therapeutics, Palobiofarma S.L., and others. Brace for groundbreaking treatments such as ARQ-151 and Ensifentrine, poised to revolutionize PDE inhibitor therapy worldwide. Ready to explore the future of healthcare? Request your free sample report now: https://lnkd.in/gjBnzW2a #PhosphodiesteraseInhibitors #HealthcareInnovation #ClinicalTrials #FutureOfMedicine #healthcare #biotechnology #lifesciences #pharmaceuticalindustry #pharmaceutical #marketresearch #marketforecast #markettrends #consulting #healthcareconsulting #consultingservices #marketforecast
PDE Inhibitor Pipeline Insight | PDE Inhibitor Mechanism of Action Insight
delveinsight.com
-
The Swiss #microbiome industry going strong! Join our discussion with the leading Swiss companies in the microbiome therapy industry next week at the #swissbiotechday!
🔬 Eager to find out about the development of microbiome therapeutics? We're pleased to announce that our Global Head of Project & Portfolio Management, Gemma Henderson, will be one of the panelists at this year's #SwissBiotechDay. Moderated by Isma Hachi, PhD, and together with Gabriel Leventhal from PharmaBiome AG, Casper Johansen from Ferring Pharmaceuticals, and Alessandra Calabrese from OM Pharma, Gemma will be giving her perspective and outlook on the microbiome field, one year after the first market launch. 🦠 Join us on April 23 at 12:00!
-
